Prof. Ti Zhang 张倜
Chief Physician, Professor
Department of Liver Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and comprehensive treatment of benign and malignant hepatobiliary tumors, including radical resection for liver cancer, gallbladder cancer, hilar cholangiocarcinoma, pancreaticoduodenectomy, and retroperitoneal tumors. Specializes in conversion therapy for advanced liver cancer.
Dr. Zhang is a Chief Physician, Professor, and doctoral supervisor at Fudan University Shanghai Cancer Center. Trained under Academician Tang Zhaoyou, Dr. Zhang completed a one-year visiting scholarship at MD Anderson Cancer Center (2009–2010). Previously worked at Tianjin Medical University Cancer Institute and Hospital (2005–2020) before joining the current department in 2021.
Professional roles
- Standing Committee Member, Liver Cancer Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Biliary Tract Tumor Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhang Ti). Papers usually list the name as Ti Zhang or Zhang T.
Selected publications
24 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Death Discov, 2026 (senior author): APOA2-mediated endothelial mesenchymal transition and cancer lipid metabolism reprogramming confers antiangiogenic drug resistance through TGF-β. PubMed 41760604
- Am J Cancer Res, 2025 (senior author): Efficacy and influencing factors of immunotherapy crossover combined with targeted therapy in advanced esophageal cancer patients following first-line chemotherapy combined with immunotherapy failure. PubMed 40226448
- FASEB J, 2023 (senior author): Thioredoxin facilitates hepatocellular carcinoma stemness and metastasis by increasing BACH1 stability to activate the AKT/mTOR pathway. PubMed 37104068
- Front Med (Lausanne), 2023 (senior author): LDP alleviates TKI-induced proteinuria through reversing the expression of RelA in renal tissues. PubMed 36744132
- BMC Gastroenterol, 2022 (senior author): Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma. PubMed 36316630
- ACS Nano, 2022 (senior author): Chiral FA Conjugated CdTe/CdS Quantum Dots for Selective Cancer Ablation. PubMed 35969155
- Front Oncol, 2021 (senior author): Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study. PubMed 34868921
- Cancer Manag Res, 2021 (senior author): The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib. PubMed 34522141
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion